Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
QuintilesIMS
Teva
Accenture
Express Scripts
Deloitte
Argus Health
Mallinckrodt
Boehringer Ingelheim

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUCINACTANT

« Back to Dashboard

Clinical Trials for Lucinactant

Trial ID Title Status Sponsor Phase Summary
NCT00004500 Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome Terminated Windtree Therapeutics Phase 3 OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
NCT00215540 SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Terminated Windtree Therapeutics Phase 2 SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS).
NCT00215553 KL₄Surfactant Treatment in Patients With ARDS Terminated Windtree Therapeutics Phase 2 Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
NCT00578734 Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old Completed Windtree Therapeutics Phase 2 Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).
NCT00807235 Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants Terminated Windtree Therapeutics Phase 2 To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
NCT00934362 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease Completed Cystic Fibrosis Foundation Therapeutics Phase 2 Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with cystic fibrosis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lucinactant

Condition Name

Condition Name for Lucinactant
Intervention Trials
Respiratory Distress Syndrome 3
Premature Birth 1
Meconium Aspiration 1
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lucinactant
Intervention Trials
Respiratory Distress Syndrome, Newborn 5
Respiratory Distress Syndrome, Adult 5
Syndrome 3
Premature Birth 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lucinactant

Trials by Country

Trials by Country for Lucinactant
Location Trials
United States 25
Poland 12
Chile 4
Canada 3
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lucinactant
Location Trials
Pennsylvania 4
California 3
Oregon 2
New York 2
Nebraska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lucinactant

Clinical Trial Phase

Clinical Trial Phase for Lucinactant
Clinical Trial Phase Trials
Phase 3 1
Phase 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lucinactant
Clinical Trial Phase Trials
Terminated 4
Completed 2
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lucinactant

Sponsor Name

Sponsor Name for Lucinactant
Sponsor Trials
Windtree Therapeutics 8
National Heart, Lung, and Blood Institute (NHLBI) 1
University of North Carolina, Chapel Hill 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lucinactant
Sponsor Trials
Industry 8
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Federal Trade Commission
Cerilliant
Healthtrust
Merck
Baxter
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.